Hugo Vance: Lila, hello — I have been thinking about the 1890s all morning, which is either a professional habit or a warning sign.
Lila Soto: Mm, I feel like both can be true — what happened in the 1890s?
Hugo Vance: Electrotherapy. Wealthy patients, plausible-sounding science, no peer review, dramatic claims about what electricity could do to the body. We know how that ended. I keep returning to it because of a headline I saw — Bryan Johnson, July 2026, announcing he had made a self-clone he calls 'baby Bryan' for future organ harvesting.
Lila Soto: Wait — 'baby Bryan' is what he actually called it?
Hugo Vance: That is the brand name, yes. What he actually did was reprogram his blood cells into induced pluripotent stem cells using Yamanaka factors — which is real, documented biology — and then described that as cloning himself as a child. Scientists pushed back immediately, noting that iPSC creation is categorically not human cloning, and that organ growth from iPSCs is still an unsolved problem.
Lila Soto: So the science happened, kind of — but the *story* he attached to it is something else entirely. And that's the thing I want to understand, because that framing — 'Don't Die,' aging as an engineering problem, baby Bryan — that doesn't feel like miscommunication. It feels like the actual offer.
Hugo Vance: Yes, and that's actually where the thing breaks — because the offer and the science are doing completely different work. Growing transplantable organs from iPSCs is described by scientists as a major unsolved scientific challenge. Not a near-future therapy. Not something Johnson can schedule. And yet Project Blueprint presents it as a personal roadmap. That gap is not a miscommunication. It's a structural feature.
Lila Soto: Hm — and then the diagnosis lands.
Hugo Vance: Right — but the part that doesn't fit is this. Project Blueprint costs millions annually. There is a team of medical professionals. He is measuring hundreds of biomarkers — lipid panels, inflammatory markers, glucose, the whole architecture. And he still develops autoimmune gastritis. An incurable condition where the immune system attacks the stomach lining. Which — well, you see, that is not a minor footnote. That is the biomarker density failing at the most basic promise.
Lila Soto: Hold on — so the measurement didn't predict it or prevent it?
Hugo Vance: That is what's being reported, yes — I want to hold that as 'what's being reported' because the clinical timeline isn't fully documented publicly. But if accurate, it suggests either the biomarkers we track don't predict what we think they do, or optimization itself has limits nobody in the longevity space wants to name. TIME Magazine in January 2026 noted that many longevity scientists say Johnson promotes unscientific advice and gives aging research a bad name. That verdict preceded the iPSC announcement. It now feels — I mean, prophetic is too strong, but it rhymes.
Lila Soto: And the social media response after the autoimmune diagnosis — longevity-focused medical accounts specifically — was overwhelmingly skeptical. Like, that diagnosis became the citation people kept reaching for.
Hugo Vance: Indeed. And there's a structural point underneath that. Project Blueprint is structurally unreplicable — millions of dollars, a full medical team. So n-of-1 self-experimentation with those resources cannot generalize. Which is — and we'll get to this — not entirely different from what's happening with the rapamycin arc and the menstrual blood project. Same skeleton, same absence of IRB, same Blueprint brand selling products alongside the data.
Lila Soto: And that same skeleton is exactly what the rapamycin arc is. Like — he starts in 2019, right? Testing it at 5 mg, 6 mg, 10 mg, weekly, biweekly, adjusting the schedule. And skin infections show up. Elevated glucose. Abnormal lipids. And he keeps going for five years until September 2024. I mean, at what point is that iteration and at what point is that... just not stopping?
Hugo Vance: That is the question. Five years of adverse effects — documented adverse effects — before discontinuation. That is not iteration in any clinical sense.
Lila Soto: It's kind of faith dressed as protocol.
Hugo Vance: Yes. And now carry that structure over to the menstrual blood project — $2.6 million, Tolo's samples stored, disease markers, microplastics, PFAS, endocrine-disrupting chemicals. Johnson says it fills a real gap in uterine biology, which, well, I won't dismiss — that gap does exist. But there is no IRB. No peer-reviewed output. And the samples are being held under Blueprint, the same commercial entity selling supplements and skincare.
Lila Soto: Oh — so the data lives inside the brand.
Hugo Vance: A biotech compliance officer would call that a structural conflict of interest baked into the architecture. It is not incidental. The research gap may be genuine — I actually think it is — but unverifiable and unrefutable are the same condition. You cannot confirm it, you cannot challenge it.
Lila Soto: And that's what connects all of it, I think — the rapamycin arc, the menstrual blood project, the autoimmune gastritis diagnosis. N-of-1, no control group, no external oversight. The spectacle is what circulates. The corrections happen downstream, quietly.
Hugo Vance: And then Nature profiles his methods in 2026. Scientific American publishes a critical analysis of the rapamycin experiment. TIME platforms him in January 2026 and reports scientific criticism in the same issue. These are not tabloids. These are credentialed outlets doing real journalism — and every piece of it, the profile and the critique both, makes him larger. I cannot resolve that. I've been sitting with it and I genuinely cannot.
Lila Soto: Yeah — and 'baby Bryan' forced a mass-audience conversation about iPSCs that probably would not have happened otherwise. I mean, I don't know that the net effect on public understanding is positive. But I'm not sure it's negative either. That feels like an honest place to stop.
Hugo Vance: It does. Neither of us knows. Which is, I think, the actual finding. Good thinking today.
Lila Soto: You too. Genuinely.
